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Abstract: Identifying new and even more precise technologies for modifying and manipulating
selectively specific genes has provided a powerful tool for characterizing gene functions in basic
research and potential therapeutics for genome regulation. The rapid development of nuclease-based
techniques such as CRISPR/Cas systems has revolutionized new genome engineering and medicine
possibilities. Additionally, the appropriate delivery procedures regarding CRISPR/Cas systems are
critical, and a large number of previous reviews have focused on the CRISPR/Cas9–12 and 13 delivery
methods. Still, despite all efforts, the in vivo delivery of the CAS gene systems remains challenging.
The transfection of CRISPR components can often be inefficient when applying conventional delivery
tools including viral elements and chemical vectors because of the restricted packaging size and
incompetency of some cell types. Therefore, physical methods such as microfluidic systems are
more applicable for in vitro delivery. This review focuses on the recent advancements of microfluidic
systems to deliver CRISPR/Cas systems in clinical and therapy investigations.
Keywords: CRISPR; microfluidics; genome; Cas9 protein; tissue engineering
1. Introduction
Genome modification including deletion and modification of DNA strands at tar-
get points has created high-light apertures to improve clinical therapy. The first clinical
trial of gene therapy in children with severe ADA-associated combination immunodefi-
ciency (ADA ID SCID) was injected with T cells, which have shown a modification in
the ADA gene [1,2]. Although the first step in integrating transgenes through homolo-
gous recombination has been taken, clinical trials in the next 40 years have been altered
to apply a new endonuclease-based gene-editing method with higher efficiency. These
approaches contain zinc finger nucleases (ZFNs), Effective Nucleases such as Transcription
Activators (TALENs), and regular and intermediate palindromic replications CRISPR/Cas
endonucleases, which is a cleft DNA endonuclease that recognizes and connects to tar-
geted sequences [3,4] The potential off-target properties of CRISPR/Cas edited human cell
lines have been highlighted in several in vitro and in vivo studies [5,6]. The first CRISPR
human clinical treatment on CRISPR/Cas9 modified immune cells started at West China
Hospital to remedy patients with lung cancer in 2016 [7,8]. Later, a scientist began the
birth of CRISPR-edited neonates in humans, simultaneously conducting clinical trials of
CRISPR genome-editing therapies in China and the United States for cancer therapy and
β-thalassemia, respectively [9].
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Although CRISPR technology has indicated elementary success with medical and
ethical rigor, delivery within the genome editing operating system remains challenging.
Despite viral vectors showing high efficiencies in the delivery and expression of genes, virus
transmission techniques are generally concerned about their potential for carcinogenicity
and immunogenicity. Recently, advances in non-viral transmission systems have been
created with the development of a wide range of carriers such as nano, micro and channels
with a diversity in targeting specific changes, so that in cultured cells or in vivo, physical
delivery has been used to provide DNA encoding via plasmids [10].
In this review, we focused on examining how to design the CRISPR/Cas gene edit-
ing and detection tools and the subsequent delivery of these systems by relying on the
microfluidic method to the intended gene population in vitro and/or in vivo studies to
attain efficient gene editing for clinical applications.
2. Limitations of Previous Automated Delivery Technologies
Although microfluidics can provide the researcher with many advantages, it is not a
cure-all. Indeed, many features of microfluidic systems that were once supposed critical to
their use or adoption are now less compelling to the attendant improvements and refine-
ments in conventional technologies [11]. In simple terms, a microfluidic tool must make a
persuasive case for adoption based on factors such as analytical performance, usability, and
information yield. The advantages of transferring macroscale electrophoresis platforms to
chip-based formats are undeniable from the point of view, speed, throughput, integration
with downstream processing, and analytical efficiency. Many molecular biologists still
prefer to pour macroscale gels because these yields essentially give the same information,
albeit on longer timescales [12,13].
A detailed assessment of the material limitations on microfluidic technology is well
beyond the scope of the current discussion. Despite many efforts, the fabrication of active
mechanical components in microfluidic devices consisting of rigid materials remains a
difficult, complex, and expensive procedure, hindering the pace of device development.
The advent of soft lithography to fabricate devices in the elastomer polydimethylsiloxane
(PDMS) catalyzed microfluidic research growth in the early–late 1990s. Indeed, many new
laboratories use nothing else because of the low technology and investment threshold
required to structure with micrometer-scale resolution [14,15]. Despite its widespread use,
PDMS has many limitations and is ill suited to mass production. Conversely, glass or
silicon substrates are robust, but require sophisticated fabrication processes whose cost or
access is prohibitive to many.
Regarding the fluid manipulation in microfluidics, most suffer from disadvantages
such as a dependence on the details of fluid and surface properties, a lack of reconfigurabil-
ity, or a lack of individual valve control [16].
3. Microfluidic Devices for Gene Delivery Systems
Gene delivery is a potential method for treating different diseases including gene-
related disorders, infectious diseases, AIDS, and cancer. An important application area
for microfluidics is genomics, and in this case is instructive in understanding the drivers
of success. Microfluidics provides a natural solution to this problem by miniaturizing
and automating nucleic acid biochemistry in high-throughput formats. Small-volume
analysis can also fundamentally improve the sensitivity of genomic analysis, enabling
experiments with very limited templates. Accordingly, by scaling reactions down to
nanoliter or picoliter volumes, microfluidics simultaneously provides throughput and
economy while also enhancing performance. Gene delivery is based on the process of
introducing into a nucleus an engineered pDNA (plasmid DNA) that encodes a functional,
therapeutic gene that helps modulate cellular functions and responses. However, efficient
delivery requires the pDNA to be protected; pDNA/cationic liposome (CL) complexation
is a promising strategy for non-viral gene therapy where that liposome is produced using
microfluidic hydrodynamic focusing devices [17].
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Moreover, using microfluidics approaches, three gene transfection techniques have
been explored including electric pulse, hydrodynamic force, and optical energy. The
microfluidic device by hydrodynamic force has parallel microfluidic channels with micro-
holes for trapping single cells [18]. A vector DNA encoding extracellular signal-regulated
kinase (ERK1) protein, known for transducing signals from the cell’s environment to the
cell nucleus, was transfused into human mesenchymal stem cells (hMSC) [19]. Using the
hydrodynamic focusing of the microfluidic device, the delivery of DNA and siRNA into
several hard-to-transfect cell lines including Neuro-2A, PC12, and C2C12 cells significantly
enhanced the transfection efficiency and viability. In the literature, the inertial vortices in
an electroporator effectively mix cells and exogenous DNA. As a result, cells in such a flow
field are exposed to a complex combination of transverse advection and rotation. Indeed, a
larger cell surface area contacts the exogenous DNA and electric field, resulting in more
uniform permeabilization [20,21].
4. CRISPR/Cas9 Systems and Designing the sgRNA
The term CRISPR, or dense regular palindromic replicates, describes a new family of
DNA replication sequences presented in the prokaryotic genome. Different CRISPR/Cas
mediated genome is composed of two classes. Their multiple effector molecules character-
ize class 1 CRISPR systems. The effector molecules contain complexes that are responsible
for RNA recognition and crRNA binding. Class 1 effector molecules are similar between
the types, despite their distinct sequences. Class 2 CRISPR systems are characterized by the
presence of a single effector molecule. Types I, III, and IV Cas proteins are class 1; however,
class 2 includes types II, V, and VI Cas proteins that use distinct genome recognition and
depreciation mechanisms. There are seven different subtypes of class 1, type I CRISPR
systems. All class 1 type I subtypes contain cas3 loci that can unwind double-strand DNA
and RNA–DNA complexes to facilitate target cutting [22,23]. Like type I, type III systems
all share a standard cas locus, in this case, cas10. Cas10 encodes something similar to an
RNA recognition motif called Palm and a cyclase domain responsible for cutting. Type
III systems can recognize both DNA and RNA for cleavage. Type IV is a putative class
1 system, whereby relatively little is known about it compared to types I and III. The
most common class 2 system type is type II. Type II systems are characterized by the
presence of Cas9 and ancillary proteins cas1 and cas2. Similar to type II systems, type V
also requires tracrRNA for function. Type VI is the only class 2 system that targets RNA
for editing [23,24]. The modular nature of Cas9 has made it a versatile tool by targeting a
nuclease protein to amplify both target DNA strands by guiding RNA sequences. It has
been performed in specific nucleic acid locations for focused analysis in human and mouse
cell lines [25].
Class 2 type II classification includes the CRISPR/Cas9 system and the system ob-
tained from the Streptococcus pyogenes bacteria, so the most extensively used of the Cas9
proteins is related to this bacteria. Cas9 is a wild-type protein with two nuclear modes,
HNH and RuvC, and the targeted activity of Cas9 can be driven by two RNA fragments
that form a dual state such as crRNA and CRRNA activator trans (tracrRNA). Activation
of the CRISPR system begins with the transcription of repetitive sequences to the CRISPR
RNA precursor (pre-crRNA) and is then cleaved into CRRNA by a tracrRNA at its 5 ends
with fused CR-ARNA [26]. The adult crRNA-tracrRNA product, using RNase III and cas9,
forms an RNA-endonuclease complex consisting of tracrRNA, crRNA, and Cas9. This
set demands the DNA sequence to play the abutting Prospasaker (PAM or short DNA
sequence) that complements the CRRNA and is recognized by the CRISPR/Cas system.
crRNA guides deliver Cas9 to the target sequences, and the combination of crRNA in the
complementary defined site as a structural alteration cleaves the target site with activating
nuclease domains in Cas9. Cas9 disports the complementary cr-RNA sequence with the
HNH domain as well as cleaves the opposite strand and produces its end by a RuvC-like
domain.
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Wild-type Cas9 and engineered mutations are combined with other functional protein
domains as a ligand and provide the ability to design new CRISPR systems that can be
turned off, activated, epigenetically modified, enhanced, or even (DNA and RNA) single
base editing. Bifurcation can be generated by CRISPR/Cas9-mediated gene modification
in two ways: terminal non-homologous binding (NHEJ) and homologous repair (HDR).
NHEJ is the dominant repair pathway that tends to make errors, although it is an efficient
repair pathway that generates indels, leading to frame change mutations and subsequently
dysfunctional genes [27]. In tumorigenesis, the CRISPR/Cas9 system can generate double-
strand bounds within the exon sequences of the mutated alleles that NHEJ renovates to
create indels that interrupt the oncogenes. The HDR pathway often happens in the form
of single-stranded oligodeoxynucleotides (ssODNs) to correct point mutation or the exact
integration of a functional site into the genome of the target cells that can be used in gene
therapy [28].
The usage of small molecules as an inhibitor factor such as Scr7, shRNA, and proteins
that affect DNA ligase IV (essential enzymes in the NHEJ and RS-1 pathways) stimulate
the human HR RAD51 protein, rather than mechanisms of DNA repair leading to HDR
pathways. Additionally, Cas9 sgRNA and nuclease transition to the late G2 phase of the
cell cycle or a combination of Cas9 nuclease to the Geminin protein to utilize the optimal
time of homologous repair pathways in the late S and G2 phase [4,29].
One of the requirements for successful modification of the eukaryotic genome using
the CRISPR/Cas9 system is the presence of the guide RNA (sgRNA or crRNA/duplex
crRNA/tracrRNA) Cas9 protein complex and the introduction of mRNA or DNA. It is
a therapeutic approach in which the genome of specific cells is re-transplanted into the
patient in vitro, and then the modified cells for therapeutic effect. This method avoids this
problem by accurately editing the cello type, creating an opportunity for successful editing
screening [30].
5. The other CRISPR/Cas Approaches for Diagnosis
In past studies, CRISPR-associated methods have been used to find nucleic acids by
using different CRISPR-associated CAS effectors like Cas12 to detect single-stranded DNA
(ssDNA). Cas12 is a compact and efficient enzyme that creates staggered cuts in dsDNA.
Cas12 processes its guide RNAs, leading to increased multiplexing ability. Cas12 has
also been engineered as a platform for epigenome editing, and it was recently discovered
that Cas12a can indiscriminately chop up single-stranded DNA once activated by a target
DNA molecule matching its spacer sequence. This property makes Cas12a a powerful
tool for detecting tiny amounts of target DNA in a mixture [31]. Cas12a nuclease, class
II CRISPR/Cas12a type V, is capable of the procedure from pre-crRNA to mature crRNA
without the existence of tracrRNA compared to CRISPR/Cas9 systems, thus diminishing
the plasmid size. Cas13 is an outlier in the CRISPR world because it targets RNA, and not
DNA. Once it is activated by a ssRNA sequence bearing complementarity to its crRNA
spacer, it unleashes a nonspecific RNase activity and destroys all nearby RNA regardless of
their sequence. The microbial CRISPR effector Cas13a (previously named C2c2) showed
the other (Cas) effectors and a triggered cleavage capability of nontarget single-stranded
RNAs (ssRNAs) in the surrounding. It was recently used as a genome editing tool, which
is considered as a powerful molecular scissor to apply in the genome editing program.
This method suggested various other CRISPR/Cas9 or Cas12a applications for genome
therapy editing including clinical strategies for human immunodeficiency virus infection
and cancer immunotherapy (B-cell leukemia and acute T-cell lymphoblastic leukemia) [32].
Cas13a, Cas13b, Cas13c, and Cas13d are four subtypes of the massive Cas13 family
that can bind and degrade RNA in a programmed manner, shield bacteria from RNA
phages, and function as a substrate. Additionally, regular cross-linked palindromic rep-
etitions (CRISPR)-Cas13a, formerly known as CRISPR-C2c2, is the recently identified
CRISPR-Cas RNA system RNA with unique single-strand characteristics to manipulate
RNA [33]. RNA degradation activity (ssRNA) destroys nearby RNAs, regardless of their
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sequence. When coroa binds to a CRISPR-RNA (crRNA), it forms an effective set of effec-
tors targeting CRRNA-guided RNA. Cas13a is the newest CRISPR-Cas system, belonging
to the Class 2 system and type VI. In addition, for the first time in Leptotrichia Shahii,
anaerobic Gram-negative rod bacteria were identified as part of the natural oral and in-
testinal flora [34,35]. Gootenberg J et al. incorporated the parallel effect of an ortholog of
Cas13a from Leptotrichia Wadei with recombinase polymerase amplification (RPA) that
can be coupled with T7 transcription to convert amplified DNA to RNA for detection
by LwCas13a as well as isothermal amplification to establish a CRISPR-based diagnostic
(CRISPR-Dx), providing rapid DNA or RNA detection with attomolar sensitivity and
single-base mismatch specificity [36,37] (see Figure 1).
Although the CRISPR/Cas9 system has been developed for several disease models,
there are several challenges to translating this technology. The main factors are needed to
be identified to impress the therapeutic conclusion of gene editing with the CRISPR/Cas9
technique [38]. Selecting an appropriate nuclease substrate and designing sgRNAs appro-
priately as well as certifying a suitable transition of editing approaches to purposed cells
in vivo or in vitro are the first and second barriers to efficient delivery.
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high potential effect through the adhesion into the host sequences. Therefore, lentivirus 
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6. Methods of Delivery CRISPR/Cas System Viral Transduction
Tw essential agents, Cas9 nucle s s and sgRNAs, ar essential for the functional
activity of CRISPR/Cas9. Viral vectors are exploited t deliver genes due to the relatively
high potential effect through the adhesio into the host sequences. Therefore, lentivirus
vectors have been used to express Cas9 and gRNAs in organism cells and can be handy over
specific sgRNAs as a knockout library in geno e-scale based on CRISPR/Cas9 to screen
gene activity cancer cells [39,40]. Furthermore, AAV is a nonpathogenic parvovirus that
can be effective in gene delivery due to its low immunogenicity and decreased tendency of
association into the host sequence and around 0.1−0.5%. The DNA packaging size of these
viruses is limited to about 10 to 18 kb in length [41,42]. The CRISPR DNA entailing 1368
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amino acids translated with over 4.1 kb DNA sequences is often used for a viral vector and
added in multiple viral vectors that increase the processing time and cost for delivery [43].
Non-Viral Delivery
Non-viral vectors showed a decreased immunogenicity in comparison to other vectors.
Additionally, the synthesize of these vectors is simple and compatible with the synchronous
transfer of sgRNAs [44]. According to the literature, there are three non-viral principles
for transferring the Cas9 nucleases: the DNA containing Cas9 gene, mRNA expressing
Cas9, and Cas9 protein [45]. Cas9 (CRISPR associated protein 9, formerly called Cas5,
Csn1, or Csx12) is a protein that plays a vital role in the immunological defense of certain
bacteria against DNA viruses and plasmids and is heavily utilized in genetic engineering
applications. Its principal function is to cut DNA and thereby alter a cell’s genome.
As mentioned, Cas9 endonuclease can transfer to the host cell as mRNA. The change
to the mRNA of Cas9 hampered the integration of plasmid DNA into the host genome.
Additionally, delivery of Cas9 nuclease as a mRNA progenitor skelps the starting of the
gene-editing process associated with CRISPR/Cas9 because it bypasses the Cas9 cDNA
transcription [46,47]. Using Cas9 mRNA instead of DNA bypasses can be accomplished in
the cytoplasm. In addition, the usage of Cas9 mRNA leads to instantaneous expression
and eventual elimination from the body [48]. Some studies have shown that transfection of
Cas9 mRNA and sgRNA by microinjection and physical delivery only causes out-of-target
mutations in most cases, but microinjection is only feasible for in vitro experiments and
specific approaches [38,49].
Although the Cas9 expression DNA is more stable and cost-effective than the Cas9
mRNA/protein, the important matter regarding the application of Cas9 expression DNA
is DNA nuclear entrance [50]. The approach of plasmid DNA is harassed by accidental
fusion of the plasmid DNA into the host sequence that is most severe to cells due to
plasmid DNA presented to cells [51–53]. Additionally, cas9 protein is transferred to the
mature sgRNA to manufacture a ribonucleoprotein (RNP) [54]. The complex of sgRNA
does not require transcription or translation [55] and Cas9 RNPs facilitate the delivery of
genomic on-target double-strand bindings after cutting by endogenous proteases [10,56].
CRISPR/Cas9 non-viral transition has been accomplished via a synthetic vector so that the
process components contain the sgRNA and Cas9 nuclease encapsulates within a lipid [57],
polymer, or inorganic carrier. Furthermore, this procedure was applied with the integration
of the sgRNA/Cas9 nuclease into peptide sequences [58,59] (see Figure 2).
Synthetic vectors have been engineered to target specific cell populations in vivo by in-
corporating surface ligands onto vectors that would recognize and bind to distinct receptors
on the target. These ligands can take the form of organic molecules. For example, the fusion
of polyethene glycol-succinyl-Chol liposomes and folic acid molecules was undertaken by
using the vector of CRISPR/Cas9 in ovarian cancer therapy. Angiopep-2, like an aptamer
or protein/peptide, permits the vectors to differentiate between healthy tissues and tumor
cells [60,61]. Recent non-viral methods to present Cas9/sgRNAs into cells in vitro and
in vivo experiments have emphasized the physical and chemical approaches [62]. Chem-
ical delivery exploits lipid vesicles and polymers based as vector chemicals to represent
load into purposed cells; these vectors encapsulate plasmid DNA and mRNA related
genetic editing [63]. Inorganic components such as gold nanoparticles, carbon nanotubes,
and graphene also indicate favorable nucleic acid and protein transition [42]. Microinjec-
tion, electroporation, and cell mechanical transformation have illustrated the ability of
Cas9/sgRNAs transfection [64,65]. Electrical, thermal, and mechanical forces can provide
energy for physical transfection as they affect the cell membrane to permit the delivery of
the loaded molecule into the cell [66]. In vivo electroporation, as a gene-editing tool, has
indicated the transfection of the genetic materials into mice epidermis tissue. Likewise,
a nano-needle of silicon can transfer plasmid DNA encoding the VEGF gene into the
mice muscles, progressing neovascularization in the target tissue [67]. Since the physical
delivery method is still too aggressive for human clinical applications applying vectors,
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this approach is superior for in vitro and ex vivo genome editing applications [68]. In this
regard, several promising ex vivo clinical trials have been performed using engineered cells
that rely on viral delivery to modify genomes. For instance, a clinical approach employing
engineered T cells and through physical transfection via high-throughput ex vivo genome
editing can improve cancer immunotherapy [69].
Mechano-transfection uses mechanical energies to form pores in the cell membrane
through physical contact with a solid structure or a shear force from the circumambient
fluids. The created pores permit specific materials to the entrance or diffuse into the cell
cytoplasm. As a traditional mechanical delivery method, the microinjection method uses
the buffer containing these components (genes including CRISPR or materials) injected
directly through a micrometer-sized capillary into the intracellular space. Micro and nan-
otechnologies have utilized a mechanical portion platform to improve gene and germline
editing such as single-cell applications in clinical applications [5,70,71].
7. Microfluidic Methods and Clinical Applications
Nowadays, one of the best approaches to deliver materials and cells is by using
microfluidic channels and chips. The chips supply a suitable substrate for cell manipulation,
drug screening, and characterization of the exosome. Furthermore, this device is useful
for pathogen and cancer detection because of its high throughput, low cost, flexibility, and
controlling fluid or gas flow [72,73]. The typical structures of a microfluidic chip like inlet,
channel mixer, and outlet (or signal detector) improve gene-editing applications. Specific
microfluidic devices have been fabricated using micro-/nanofabrication techniques. The
new generation of microfluidics modifies nanoliter volumes of liquids or more minor and
interconnected micron-sized dimension channels to provide the automated delivery of
stimulatory factors to cells [74].
It is noteworthy that the manufacturing methods are different according to the ma-
terial properties. The microfluidic chips manufactured in inorganic materials (silica and
glass) or organic materials (polydimethylsiloxane, polystyrene, polymethyl methacrylate,
or PMMA, and composite materials) [75]. Glass, silicon, and polydimethylsiloxane are
the crude materials of biomedical microfluidic systems using biocompatible materials
suitable for in vivo and in vitro situations and easy integration with electronics. The main
biomedical analysis and finding methods are based on optical microscope technology in
which the properties of silicon transparency are utilized for biomedical applications [76,77].
The liquid polydimethylsiloxane (PDMS) is prepared at high temperatures, so it is usually
ripe to create soft lithographic patterns for different approaches, especially biomedical
applications, tissue models, and drug testing. Some studies have shown the usage of a
variety of applications and materials such as glass-based microfluidic by photolithograph-
ically etching and poly (N-isopropylacrylamide) PIPAAm with the biocompatibility of
PDMS in detecting DNA samples and performing the laminar architecture of the heart
ventricle [72,78,79].
Although some disadvantages of PDMS include the sorption of nonspecific and surface
molecules, increased adsorption of hydrophilic molecules, the increment of incompatible
solvents and reagents, and the release of uncrosslinked small PDMS molecules [80], high
throughput biomedical microfluidic systems including polymethylmethacrylate (PMMA),
cyclo-olefin copolymers (COC), thermoset polyester (TPE), polycarbonate (PC), polystyrene
(PS), and perfluoropolyether (PFPE) are suitable for developing the microfluidic indus-
try [81,82].
Design and production technology regarding the function of the microfluidic systems,
diverse structures including arrays and multi-channels and microfluidic technologies offer
an extensive range of facilities for component modification containing transportation,
separation, trapping, and enrichment using hydrodynamic, acoustic, electrical, optical
tweezers, and magnetic techniques. Additionally, recent micro- and nano-engineering
progression offers two methods to administer particles by self-driven micro-robots in
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hydrogen peroxide solution and non-reciprocally beating cilia acting to deliver fluids and
materials in biological systems [83,84].
Previous studies have reported that the hydrodynamic, electrical, and acoustic are
the most popular tools for particle manipulation explained in CRISPR/Cas studies [85].
Additionally, microfluidics has been used for the detection of proteins (e.g., microfluidic
western blotting), nucleic acids (e.g., PCR, direct detection, and DNA sequencing of nucleic
acids on microfluidic chips), single cells, specific organs (organ-on-a-chip), and clinically
critical small molecules [86–88].
The self-assembly method for fast chemical reactions and complex structures made
by the injection and mixing mechanism is a new approach that depends on the channel
structure for biomedical detection. For example, Y- and T-shaped multi-channels and three-
dimensional junctions in the lined conduit are well-designed structures for injection [89].
In this technique, the concentration of reagent, shear force, and injection rate must be
controlled [90].
To construct a 3D microfluidic system, the extracellular matrix (ECM) is the essen-
tial part of this cell-based 3D accede due to the suitable cell survival and its growth
condition [72]. Therefore, the use of the ECM in the microfluidic system leads to the
formation and maintenance of the binding structure of adjacent cells in vivo to provide
a platform for imitation of the real 3D microenvironment for medical models [91]. The
ECM in the microfluidic approach provides pivotal functions including supplying an
ideal microenvironment in the system for cell growth, differentiating cell to vital organs,
and manufacturing high potency models for cell aggregation, spheroid, tissue or organ
models [92].
The examinations in 3D HTBMS were performed on a varied range of applications
such as 3D cell culture based on microfluidics and the organ-on-a-chip approach [93]. Zhu
et al. (2019) showed a novel 3D micro-assembling strategy assisted by 3D printing, enabling
the molding of 3D microstructures such as LEGO® parts from 3D-printed molds. In this
study, the molded PDMS LEGO assembled into a 3D-cell culture chamber interconnected
with vertical and horizontal perfusion microchannels such as a 3D channel network by
multi-directional electric frequency scanning (3D µ-electro-transfection). This generates
local fluctuation to enhance mass transport via the interconnected vertical and horizon-
tal perfusion microchannel array, which was reconstructed by this 3D printing-assisted
molding and assembling process, thus improving cell transfection efficiency [94].
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because creating the genetic deletion in PD-1 was proven advantageous in engineering
T cells for cancer and tumor immunotherapies. According to this study, microfluidic cell
deformation-based Cas9 RNP delivery provided accurate genome editing in T cells and
cancer immunotherapy [95].
In another study, Han et al. (2016) reported a loss of CRISPR-Cas9-mediated kinase
function for cancer cell deformation and invasive potential in a properly functioning mi-
crofluidic chip. They combined the CRISPR-Cas9 screen with chip-based cell deformation
sorting to identify tumor-inhibiting kinases and designed a unique cell purification system
to sort highly deformable cells in a high-efficiency method. This microfluidic device allows
flexible cells with high ductility and metastatic tendency to cross micro-barriers and exit the
separation chip under hydrodynamic forces, while rigid cells remain trapped [52]. Initially,
microfluidic deformable chip cell separation or MS-chip (mechanical separation chip) was
designed and validated to separate flexible cells from rigid cells by hydrodynamic forces
(separating structure consists of two million rectangular micro-posts 30 mm in height with
gap distances decreasing from 15 mm to 6 mm). Their study provided a new perspective
for the large-scale coalition of the lab-on-chip example to rapidly screen gene function
based on the CRISPR knockout system [97].
Because cancer is a heterogeneous disease that is genetically very different and relies
on different pathways for survival, chemical susceptibility testing shifts to a more personal
approach. As expected, one of the preferred methods is to use the CRISPR approach
to screen and recognize genes involved in cell proliferation in mammalian models [98].
Sinha et al. first showed automatic gene editing through digital microfluidics by a system
to decode the genes related to lung cancer in transfer and deletion efficiency with a
standard imaging pipeline. Additionally, gene-editing evaluation in this study targeted edit
automation of the MAPK/ERK pathway, especially the RAF1 gene, to show the function
of digital microfluidics in culturing lung cancer cells for a long time and implement gene
transfection and knockout procedures for cancer therapy [74,99].
Among the technologies that have been realized for the delivery of exogenous molecules
into living cells in vivo or in vitro experiments, electroporation has successfully been recog-
nized as one of the most varied and flexible approaches with the most transfection ability
and minimum cell toxicity. mRNA delivery can be demonstrated efficiently into mouse
zygotes for CRISPR/Cas9-based genome editing and used to extract genomic DNA or
release other intracellular components from cells through microfluidic systems [100]. Duo
to the shortage of the high throughput tool in genetic screenings, cellular analysis, and
delivery, selective release of intracellular molecules at the single-cell level and detection of
kinase translocation several groups including Geng et al. [101], Bao et al. [102], and Wang
et al. [103], respectively, have improved the diversity of minimized electroporation devices
by obtaining the advantages of micromachining.
In this regard, Bian et al. developed a high-throughput electroporation microsystem
with an optimized superhydrophobic feature. They used the micro-well array to attain
controlled conditions in each micro-well and the digital electrode in micro-wells to in-
crease efficient transfection and electroporation of ingredients such as sgRNA into the cells.
Two plasmids encoding enhanced green and red fluorescent proteins were successfully
delivered into HeLa cells on a 169-microwell array chip. Additionally, the sgRNA was con-
ducted through selective electroporation into 293T cells expressing the Cas9 nuclease [104].
Previously, Bian’s group developed a superhydrophobic microwell array chip (SMARchip)
for enhanced screening in cell culture. The SMARchip platform performed the successful
combining of stem cells with chemical and mechanical elements. During electroporation,
each electrode unit made contact with the corresponding microwells through droplet
connections and the sgRNAs within cells were thoroughly examined in this approach [105].
DiTommaso et al. used a genome-wide approach to study optimized electroporation
treatment and recognize significant disruptions in the expression profiles in transcripts of
human T cells. They found that a microfluidic membrane deformation technique denomi-
nated “squeezing” had lesser side effects than electroporation. They determined changes
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at the genetic level with full transcriptome microarrays, accredited protein expression,
and specific phenotype through some markers. In the direction of comparing the elec-
troporation and cell squeezing, they selected two cell types that are common targets for
gene engineering: CD4+ HSCs and T cells. Delivery of fluorescent-tagged dextran to cells
isolated from human donors via electroporation or cell-squeezing protocols was performed,
and Cas9 protein–gRNA RNP complexes (Cas9 RNPs) were transfected to target PD-1 via
gene-editing of both technologies. As mentioned in previous studies, Cas9 RNPs process an
arresting system for manipulating the genomes of primary cells, especially T cells [106,107].
To evaluate the function of this system, they selected two critically expressed genes of T
cell, IFN γ, and IL-2 to characterize their expression levels after treatment with the delivery
process. As a result, cells targeted to a mechanical membrane disruption-based delivery
mechanism or cell squeezing had minimal aberrant transcriptional responses, and T cells
edited with similar efficiency via cell squeezing and microfluidic approach compared to
electroporation demonstrated the expected tumor-killing advantage.
Their work suggests that mechanical membrane disconnection coupled with diffusion-
mediated delivery significantly decreases unintended negative consequences and func-
tional deficiencies. The significant differences in outcomes from the two techniques empha-
sized the importance of intracellular transfection methods on cell function research and
clinical applications [108].
Cas9 was extracted from many species of bacteria and applied in biotechnology, so
the capability of Cas9 detecting in S. pyogenes, S. aureus, N. meningitides, and S. thermophiles
was developed using approved antibodies. The use of Cas9 varied species due to having
specific properties in their genomes improved structures with thermal stability and smaller
size [43,109,110]. Phaneuf C et al. exerted a centrifugal microfluidic platform, multiple
Cas9 species, and a dCas9 (dead Cas9) integrated into effector domains to detect both Cas9
protein levels and the function of catalytic nuclease.
The Dcas9 scaffold is composed of two components including the nuclease domains
inactivated by single-base mutation and the Cas9 attached guide-RNA remaining in the
DNA sequences. Targeted mutations have been created by integrating a cytidine deami-
nase domain to dCas9 [25]. Microfluidic discs were made from polymethyl methacrylate
(PMMA) and PSA film as a pressure-sensitive adhesive. Indeed, the laser beams cut sec-
tions of PMMA and PSA along with alignment holes that allow for gathering efficiently
via spired pins. The layers were then placed against each other, and the disks were placed
in a vacuum for 24 h before being used. Each of the three centrifugal microfluidic layers
constructed with CO2 laser and two ends of the structure was composed of a rigid PMMA
layered assembly with an adhesive layer.
To detect Cas9 species, the silica microparticles combined with the CRISPR inhibitor
AcrIIC1 protein binds to the conserved HNH domain from many species of Cas9 [111].
Because this, a protein accompanied by a specific antibody detector could identify the
Cas9 in species such as N. meningitides, G. stearothermophilus, and C. jejuni [112,113].
They have shown dramatic enhancement through a manual microfluidic tool to detect
fluorescence signals and trace Cas9 multiple species directly in the bodily fluids that are
useful in preclinical experiments [25]. CRISPR-based diagnostic methods have aroused a
high enthusiasm due to their efficiency, sensitivity, and high proprietary [114].
Brush et al. integrated the first clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas13a-powered microfluidics with an electrochemical signal readout to
identify microRNAs, increase sensitivity as a target amplification, and selective diagnostic
test in another publication. However, there is an urgent need to develop handmade
methods for miRNA detection in clinical trials, where the quantification of the potential
tumor marker microRNAs can be recognized without amplifying genomic sequences. They
combined the CRISPR technology with an electrochemical microfluidic equipped with
the DFR technology (Dry Film photo-Resist) as a biosensor to evaluate miRNA levels
of the brain tumor marker miR-19b in serum samples of cancer patients. The specificity
of the detection is given by a specific CRISPR RNA (crRNA) that guides the Cas13a to
Materials 2021, 14, 3164 12 of 18
the target sequence of RNA [115]. After recognizing the complementary RNA sequence,
the cleavage ability of the enzyme is activated, and a reporter RNA can be used for a
quantitative assessment of RNA levels. Arranging multiple DFR foils into a platinum
patterned polyimide substrate, the electrodes, and the microchannels consisting of an
electrochemical cell, was realized to operate their functions.
As a result, this unique merger of the CRISPR/Cas13a technology with the microfluidic
biosensor equipped with an electrochemical reader, permits the detection of the target
miRNAs including miR-19b and miR-20a with a high sensitivity method [36].
Rapid and accurate adjustable molecular diagnostic tests such as CRISPR-based ap-
proaches are imperative to stop the global spread of new diseases. The spread of COVID-19
throughout the world has disclosed significant notches in clinical to react against new viral
pathogens. In one study by Ramachandran et al., the CRISPR-Cas12 system complexed
with a synthetic guide RNA, and this structure is activated when it highly binds explicitly
to target DNA and randomly cleaves single-stranded DNA through probes labelled with a
fluorophore-quencher pair. Then, they achieved an appropriate electric field gradient using
a particular ionic focusing technique such as an isotachophoresis method on a microfluidic
chip. They also combined isotachophoresis with loop-mediated isothermal amplification
to detect SARS-CoV-2 RNA in 30 min that provides automated purification of target RNA
from a raw nasopharyngeal swab sample and subsequently diagnose SARS-CoV-2 RNA
based on microfluidic-CRISPR assays. Isotachophoresis or ITP is an electro-kinetic microflu-
idic technique that uses a two-buffer system including a high-mobility leading electrolyte
and a low-mobility trailing electrolyte buffer (the combination of microfluidics and on-chip
electric field). This combination used the desired on-chip ITP to effect rapid CRISPR-Cas12
enzymatic activity and focused Cas12-gRNA upon target nucleic acid recognition. Briefly,
a novel electric field has improved the microfluidic method, which is enforceable for the
field of CRISPR diagnostics [116–118].
Table 1. The clinical application of employing microfluidic methods for gene delivery.
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8. Conclusions
The CRISPR/Cas approaches suggest advantages in gene-editing technology through
a guide RNA and CAS nuclease to recognize and manipulate the proposed DNA genome
by respecting efficiency and specificity. This versatile gene-editing system has progressed
swiftly, and various utilizations from disease diagnosis to therapeutic intermediations
have been supported through this method. However, transferring is the main subject
for accomplishing CRISPR/Cas gene editing in clinical experiments. A well-designed
CRISPR/Cas survey should consider the different aspects including attaining maximum
on-target efficiency, reducing off-target effects, and accurate transferring. In the past decade,
microfluidic technologies have been widely implemented in many fields ranging from
fundamental biological research and targeted delivery via microfluidic chips would en-
hance the use of this technology. The microfluidic device has great potential for complex
sample processing and a high level of integration, making them robust and powerful tools
in point-of-care testing. Results show that the combined microfluidic sorting systems
based on the mechanical properties of cells with CRISPR-Cas9 technologies is a potential
approach for gene editing, clinical therapy, and a genetic screening strategy that facili-
tates the rapid identification of gene function in abundant diseases. To summarize, this
genome editing application has been continued to apply novelties and vast opportunities
with close collaboration between biomedical and biomaterial researchers who can create
communication via improving impressive non-viral physical transfection methods such as
a microfluidics method for various gene-editing and therapy factors.
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